OncoSil’s Pancreatic Cancer Treatment Gets CE Mark

April 1, 2020

OncoSil Medical has earned a CE Mark for its OncoSil implant used to treat pancreatic cancer alongside chemotherapy.

The radioactive implant is placed directly in a patient’s pancreatic tumor using endoscopic ultrasound. It can also be used to treat other solid tumor types such as liver and biliary duct cancer.

OncoSil previously received a breakthrough device designation from the FDA.

View today's stories